Provided by Tiger Trade Technology Pte. Ltd.

MaxCyte Inc

1.38
0.0000
Post-market: 1.380.00000.00%19:30 EDT
Volume:435.91K
Turnover:599.33K
Market Cap:142.42M
PE:-4.13
High:1.40
Open:1.40
Low:1.36
Close:1.38
52wk High:1.87
52wk Low:0.6434
Shares:103.21M
Float Shares:93.72M
Volume Ratio:0.59
T/O Rate:0.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3338
EPS(LYR):-0.4200
ROE:-20.39%
ROA:-10.64%
PB:0.90
PE(LYR):-3.29

Loading ...

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

GlobeNewswire
·
Aug 19

MaxCyte Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

MaxCyte Reports Q2 Results, Highlights Genentech Partnership

TIPRANKS
·
Aug 13

MaxCyte Publishes Corporate Presentation on Scalable Electroporation Platform for Cell and Gene Therapies

Reuters
·
Aug 13

MaxCyte Q2 Revenue Beats Estimates

Reuters
·
Aug 13

MaxCyte Q2 FY26 Net Loss Narrows 28% to $8.9 Million; Revenue Drops 15% to $7.3 Million

Reuters
·
Aug 13

MaxCyte Q2 EPS $(0.08) Beats $(0.09) Estimate, Sales $7.271M Beat $6.475M Estimate

Benzinga Earnings
·
Aug 13

MaxCyte Q2 Cash & Investments USD 141.9 Million

THOMSON REUTERS
·
Aug 13

MaxCyte Q2 Gross Profit USD 5.6 Million

THOMSON REUTERS
·
Aug 13

MaxCyte Q2 EPS USD -0.08

THOMSON REUTERS
·
Aug 13

MaxCyte: Full Year Revenue Expected to be $30 Million to $32 Million

THOMSON REUTERS
·
Aug 13

Press Release: MaxCyte Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 13

MaxCyte Inc Expected to Post a Loss of 9 Cents a Share - Earnings Preview

Reuters
·
Aug 11

MaxCyte Enters Technology License Partnership With Genentech

MT Newswires Live
·
Jul 21

MaxCyte enters technology license partnership with Genentech

TIPRANKS
·
Jul 21

Maxcyte® Announces Multi-platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

THOMSON REUTERS
·
Jul 21

Maxcyte - Genentech to Access Maxcyte Expert Gtx Platform and Technologies for Cell Therapy Workflows

THOMSON REUTERS
·
Jul 21

MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026

GlobeNewswire
·
Jul 16

MaxCyte (MXCT) Receives a Buy from Craig-Hallum

TIPRANKS
·
Jul 04

Craig-Hallum Keeps Their Buy Rating on MaxCyte (MXCT)

TIPRANKS
·
Jun 25